Abstract
Objectives: As a selective matrix metalloproteinase inhibitor, MMI-166 specifically inhibits MMP-2 and MMP-9 activity and represses tumor invasion and metastasis. Previous studies show that MMI-166 has an anti-metastatic role in a variety of tumors. However, it still remains unclear about the exact effect of MMI-166 on human pancreatic cancer.
Methods: In this study, we showed firstly MMI-166 induced proliferation inhibition and apoptosis of SW1990 human pancreatic cancer cells in both dose- and time-dependent manners in vitro. We successfully established a human pancreatic cancer xenograft model in nude mice and verified the inhibition effect of MMI-166 on MMP-2 and MMP-9.
Results: More importantly, by using this model, we further demonstrated MMI-166 suppressed growth of SW1990 pancreatic cells xenograft in vivo by inducing cells apoptosis. In addition, we examined the expression of a series of apoptosis-related proteins and found MMI-166 inhibited the expression of c-Myc.
Conclusion: Our work demonstrates that MMI-166 may be of therapeutic value in the treatment of pancreatic cancer.
Keywords: Animal experimentation, apoptosis, cell proliferation, MMI-166, pancreatic neoplasms.
Current Signal Transduction Therapy
Title:Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells
Volume: 9 Issue: 2
Author(s): Junben Wu, Muhammad Shahbaz, Shujing Wang, Bengang Gong, Benjia Liang, Ruliang Fang, Bo Qiu, Min Jiang, Yang Li and Jun Niu
Affiliation:
Keywords: Animal experimentation, apoptosis, cell proliferation, MMI-166, pancreatic neoplasms.
Abstract: Objectives: As a selective matrix metalloproteinase inhibitor, MMI-166 specifically inhibits MMP-2 and MMP-9 activity and represses tumor invasion and metastasis. Previous studies show that MMI-166 has an anti-metastatic role in a variety of tumors. However, it still remains unclear about the exact effect of MMI-166 on human pancreatic cancer.
Methods: In this study, we showed firstly MMI-166 induced proliferation inhibition and apoptosis of SW1990 human pancreatic cancer cells in both dose- and time-dependent manners in vitro. We successfully established a human pancreatic cancer xenograft model in nude mice and verified the inhibition effect of MMI-166 on MMP-2 and MMP-9.
Results: More importantly, by using this model, we further demonstrated MMI-166 suppressed growth of SW1990 pancreatic cells xenograft in vivo by inducing cells apoptosis. In addition, we examined the expression of a series of apoptosis-related proteins and found MMI-166 inhibited the expression of c-Myc.
Conclusion: Our work demonstrates that MMI-166 may be of therapeutic value in the treatment of pancreatic cancer.
Export Options
About this article
Cite this article as:
Wu Junben, Shahbaz Muhammad, Wang Shujing, Gong Bengang, Liang Benjia, Fang Ruliang, Qiu Bo, Jiang Min, Li Yang and Niu Jun, Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells, Current Signal Transduction Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574362409666141201202706
DOI https://dx.doi.org/10.2174/1574362409666141201202706 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Medical Evaluation of Human MicroRNAs Needs to Address Recent Sequences and GC Content
Current Regenerative Medicine (Discontinued) The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
Current Cancer Drug Targets The Disposal of Reactive Carbonyl Species through Carnosine Conjugation: What We Know Now
Current Medicinal Chemistry Keeping A Breast of Recent Developments in Cancer Metabolism
Current Drug Targets Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Radioactive Nanoparticles and their Main Applications: Recent Advances
Recent Patents on Nanotechnology Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Current Drug Discovery Technologies Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research
Current Drug Targets Analytical Approaches for Assaying Metallodrugs in Biological Samples: Recent Methodological Developments and Future Trends
Current Drug Metabolism Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of β Amyloid-Induced Astrogliosis <i>In Vitro</i>
CNS & Neurological Disorders - Drug Targets MicroRNAs-Based Therapeutic Strategy for Virally Induced Diseases
Current Drug Discovery Technologies <i>DBX2</i> Promotes Glioblastoma Cell Proliferation by Regulating <i>REST</i> Expression
Current Pharmaceutical Biotechnology Nucleic Acid Carrier Systems Based on Polyethylenimine Conjugates for the Treatment of Metastatic Tumors
Current Medicinal Chemistry Brain Tumor-Related Epilepsy
Current Neuropharmacology Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research NOB1: A Potential Biomarker or Target in Cancer
Current Drug Targets Peroxisome Proliferator-Activated Receptor-γ and Its Ligands in the Treatment of Tumors in the Nervous System
Current Stem Cell Research & Therapy Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets